161 related articles for article (PubMed ID: 26729302)
21. [New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of Nephrologists form Lombardy].
Bellasi A; Cozzolino M; Malberti F; Cancarini G; Esposito C; Genderini A; Guastoni CM; Ondei P; Pontoriero G; Teatini U; Vezzoli G; Messa P; Locatelli F
G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786181
[TBL] [Abstract][Full Text] [Related]
22. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM
Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917
[TBL] [Abstract][Full Text] [Related]
23. Effect of cinacalcet cessation on hyperparathyroidism in kidney transcaplant patients after long-term dialysis therapy.
Nakai K; Fujii H; Yoshikawa M; Kono K; Yonekura Y; Goto S; Ishimura T; Takeda M; Fujisawa M; Nishi S
Clin Exp Nephrol; 2015 Dec; 19(6):1184-8. PubMed ID: 25782729
[TBL] [Abstract][Full Text] [Related]
24. Calcimimetics versus parathyroidectomy: What is preferable?
Rroji M; Spasovski G
Int Urol Nephrol; 2018 Jul; 50(7):1271-1275. PubMed ID: 29532306
[TBL] [Abstract][Full Text] [Related]
25. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
[TBL] [Abstract][Full Text] [Related]
26. Long-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis.
Chen L; Wang K; Yu S; Lai L; Zhang X; Yuan J; Duan W
Ren Fail; 2016 Aug; 38(7):1050-8. PubMed ID: 27198474
[TBL] [Abstract][Full Text] [Related]
27. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
[TBL] [Abstract][Full Text] [Related]
28. Challenges in the therapy of secondary hyperparathyroidism.
Wood C; González EA; Martin KJ
Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
[TBL] [Abstract][Full Text] [Related]
29. Mortality in dialysis patients with cinacalcet use: A large observational registry study.
Friedl C; Reibnegger G; Kramar R; Zitt E; Pilz S; Mann JFE; Rosenkranz AR
Eur J Intern Med; 2017 Jul; 42():89-95. PubMed ID: 28499709
[TBL] [Abstract][Full Text] [Related]
30. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism.
Akizawa T; Kurita N; Mizobuchi M; Fukagawa M; Onishi Y; Yamaguchi T; Ellis AR; Fukuma S; Alan Brookhart M; Hasegawa T; Kurokawa K; Fukuhara S
Sci Rep; 2016 Apr; 6():19612. PubMed ID: 27071541
[TBL] [Abstract][Full Text] [Related]
31. Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency.
Törmänen S; Pörsti I; Lakkisto P; Tikkanen I; Niemelä O; Paavonen T; Mustonen J; Eräranta A
BMC Nephrol; 2017 Oct; 18(1):323. PubMed ID: 29078759
[TBL] [Abstract][Full Text] [Related]
32. [The use of Cinacalcet in chronic kidney disease: a case report].
Russo R; Argentino G; Maresca ID; Sannino G; Memoli A; Memoli B
G Ital Nefrol; 2015; 32(4):. PubMed ID: 26252263
[TBL] [Abstract][Full Text] [Related]
33. Management of secondary hyperparathyroidism: practice patterns and outcomes of cinacalcet treatment with or without active vitamin D in Austria and Switzerland - the observational TRANSIT Study.
Pronai W; Rosenkranz AR; Bock A; Klauser-Braun R; Jäger C; Pendl G; Hemetsberger M; Lhotta K
Wien Klin Wochenschr; 2017 May; 129(9-10):317-328. PubMed ID: 28091752
[TBL] [Abstract][Full Text] [Related]
34. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.
Kawata T; Tokunaga S; Murai M; Masuda N; Haruyama W; Shoukei Y; Hisada Y; Yanagida T; Miyazaki H; Wada M; Akizawa T; Fukagawa M
PLoS One; 2018; 13(4):e0195316. PubMed ID: 29614098
[TBL] [Abstract][Full Text] [Related]
35. [Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].
Iwashita Y; Iwashita Y; Ito T; Shigematsu T
Clin Calcium; 2016 Feb; 26(2):259-67. PubMed ID: 26813506
[TBL] [Abstract][Full Text] [Related]
36. Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism.
de Francisco AL; Gillespie IA; Gioni I; Floege J; Kronenberg F; Marcelli D; Wheeler DC; Froissart M; Drueke TB;
Nefrologia; 2016; 36(2):164-75. PubMed ID: 26654696
[TBL] [Abstract][Full Text] [Related]
37. [Contemporary opinions on the diagnosis and treatment of secondary hyperparathyroidism].
Zawierucha J; Małyszko J; Małyszko J; Prystacki T; Marcinkowski W; Dryl-Rydzyńska T
Przegl Lek; 2016; 73(7):497-503. PubMed ID: 29677420
[TBL] [Abstract][Full Text] [Related]
38. Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.
Parfrey PS; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Chertow GM
Clin J Am Soc Nephrol; 2016 Mar; 11(3):539-46. PubMed ID: 26614406
[TBL] [Abstract][Full Text] [Related]
39. The effects of cinacalcet treatment on bone mineral metabolism, anemia parameters, left ventricular mass index and parathyroid gland volume in hemodialysis patients with severe secondary hyperparathyroidism.
Torun D; Yildiz I; Micozkadioglu H; Nursal GN; Yigit F; Ozelsancak R
Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):15-22. PubMed ID: 26787561
[TBL] [Abstract][Full Text] [Related]
40. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
